Suppression of silent information regulator 1 activity in noncancerous tissues of hepatocellular carcinoma: Possible association with non‐B non‐C hepatitis pathogenesis

Cancer Science

Hideyuki Konishi¹  Ken Shirabe¹  Hidekazu Nakagawara¹  Norifumi Harimoto¹  Yo-Ichi Yamashita¹  Toru Ikegami¹  Tomoharu Yoshizumi¹  Yuji Soejima¹  Yoshinao Oda² 

[1] Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

关键词: Nicotinamide adenine dinucleotide;    nicotinamide phosphoribosyltransferase;    non‐alcoholic steatohepatitis;    non‐B non‐C hepatitis;    silent information regulator 1;   

DOI  :  10.1111/cas.12653

来源: Wiley

【 摘 要 】

Abstract

Silent information regulator 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD⁺)-dependent protein deacetylase. In mice, mSirt1 deficiency causes the onset of fatty liver via regulation of the hepatic nutrient metabolism pathway. In this study, we demonstrate SIRT1 expression, activity and NAD⁺ regulation using noncancerous liver tissue specimens from hepatocellular carcinoma patients with non-B non-C (NBNC) hepatitis. SIRT1 expression levels were higher in NBNC patients than in healthy donors, while SIRT1 histone H3K9 deacetylation activity was suppressed in NBNC patients. In the liver of hepatitis patients, decreased NAD⁺ amounts and its regulatory enzyme nicotinamide phosphoribosyltransferase expression levels were observed, and this led to inhibition of SIRT1 activity. SIRT1 expression was associated with HIF1 protein accumulation in both the NBNC liver and liver cancer cell lines. These results may indicate that the NBNC hepatitis liver is exposed to hypoxic conditions. In HepG2 cells, hypoxia induced inflammatory chemokines, such as CXCL10 and MCP-1. These inductions were suppressed in rich NAD⁺ condition, and by SIRT1 activator treatment. In conclusion, hepatic SIRT1 activity was repressed in NBNC patients, and normalization of NAD⁺ amounts and activation of SIRT1 could improve the inflammatory condition in the liver of NBNC hepatitis patients.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.